



Argos Therapeutics  
Investor Relations Department  
4233 Technology Drive  
Durham, NC 27704  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

**NASDAQ: ARGS**

Last Trade: 0.22

Trade Time: 3:59 PM ET  
Aug 16, 2017

Change: -0.01  (-2.273%)

Day Range 0.21 - 0.24

52-Week Range 0.22 - 5.68


Volume 1,734,842

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 9, 2017*  
[Argos Therapeutics Reports Second Quarter 2017 Financial Results and Recent Operational Highlights](#)
- Jul 26, 2017*  
[Argos Reports Immunogenicity Results of AGS-004 in HIV Program](#)
- Jun 22, 2017*  
[Argos Therapeutics Announces Closing of \\$6.0 Million Secured Convertible Note Financing](#)
- Jun 16, 2017*  
[Argos Therapeutics Announces \\$6,000,000 Secured Convertible Note Financing](#)
- May 10, 2017*  
[Argos Provides Update on its ADAPT Trial Following Meeting with FDA](#)

## Financials [\[ View all \]](#)

- Mar 16, 2017*  
[Annual Report \(10-K\)](#)
- Jul 6, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016*  
[Quarterly Report \(10-Q\)](#)